Cell2Cure
  • Home
  • The Company
  • Research, Technology and IP
  • Clinical
  • Investor and Partners
  • Publications
  • News
  • Contact us
Select Page

Enrolment finalized in the lung transplantation ASC phase I-II clinical trial

by Backoffice | Apr 18, 2023 | Studies and testing

Patient with severe terminal lung disease may ultimately be treated with a donor lung transplantation. However, transplantation of a lung from another person elicits a strong immunologic reaction by the recipient towards the transplanted donor lung. In the worst case,...

Cell2Cure has treated the first patient with diabetic foot ulcer in the STEMFOOT (Phase I study)

by Backoffice | Feb 9, 2023 | Studies and testing

The first patient with diabetic foot ulcer was treated with Cell2Cure’s allogeneic adipose tissue-derived mesenchymal stromal cell product (C2C_ASCs) January 24, 2023 at Bispebjerg University Hospital, Copenhagen, Denmark. The STEMFOOT study is carried out in...

Ethical approval for the ASC phase I clinical trial in children with autism and leaky gut syndrome

by Backoffice | Nov 4, 2022 | Studies and testing

The Danish National Center for Ethics has November 2nd, 2022, approved the un-blinded phase I clinical trial with dose-titrating of allogeneic adipose-derived mesenchymal stem cells (ASCs) for treatment of children with autism. The project is a collaboration between...

The Danish Medicines Agency has approved a Phase I study treating diabetic foot ulcer with C2C_ASC

by Backoffice | Sep 21, 2022 | Studies and testing

Cell2Cure will be investigating treatment of patients with diabetic foot ulcus with C2C_ASC. The clinical study will be carried out in collaboration with Professor Ole Lander Svendsen and his team at Bispebjerg University Hospital, Copenhagen, Denmark. The study was...

Patient enrollment finalized in the Phase II trial testing ASC in Sjögren’s syndrome

by Backoffice | Jun 17, 2022 | Studies and testing

Aqueous Deficient Dry Eye Disease, Sjögren’s syndrome is a serious autoimmune disease that can cause serious eye and vision problems due to reduced tear production. The patient enrollment is now finalized in the randomized double-blind placebo-controlled phase II...

ASC’s enter Phase II testing in Salivary gland re-generation

by ICR-Web | Feb 10, 2021 | Studies and testing

Patients with head-and neck cancer are often treated with radiation therapy. A side-effect to this life saving therapy is reduced salivary production which has serious consequences for mouth-, and dental health and quality of life. Injection of ASCs directly into the...
« Older Entries

Recent Posts

  • Cell2Cure researched by Tech Journal »Ingeniøren«
  • Enrolment finalized in the lung transplantation ASC phase I-II clinical trial
  • Cell2Cure has treated the first patient with diabetic foot ulcer in the STEMFOOT (Phase I study)
  • The Danish Medicines Agency has approved the phase I clinical trial with cell treatment of children with autism and leaky gut syndrome
  • Ethical approval for the ASC phase I clinical trial in children with autism and leaky gut syndrome

Recent Comments

    Archives

    • May 2023
    • April 2023
    • February 2023
    • November 2022
    • September 2022
    • August 2022
    • June 2022
    • April 2022
    • February 2022
    • July 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020
    • January 2020

    Categories

    • Collaborations
    • Patents
    • Studies and testing
    • Trial results

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    © 2021 Cell2Cure | CVR.no 39401975 | Designed by ICR-Design ApS